Analysts' Top 5 Price Targets of July 1, 2025
Reading Time: 3 minutes
Ionis Pharmaceuticals [US4622221004]: Barclays upgrades to Equal Weight and Overweight and raises the price target from $51 to $57 (40% upside potential) The upgrade is based on the positive assessment of the upcoming Phase 3 data from the CORE and CORE2 trials for Tryngolza, a drug for the treatment of severe hypertriglyceridemia (sHTG). The release of the study results is expected in September 2025. According to Barclays, there is over a 90% probability that the trials will achieve their primary endpoint. In addition to Tryngolza, Ionis is making...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
